Renaissance Labs

Atlas / North America

Independent company · San Francisco, United States

Chai Discovery

A drug-discovery AI startup that released the open Chai-1 biomolecular structure model.

biologystructure prediction

San Francisco, United States

Founded
2024
Type
Independent company
Based in
San Francisco, United States
Key papers
1
Featured projects
2

Update Chai-1 is released as open source. Later models such as Chai-2 appear to be proprietary.

About

Chai Discovery is a drug-discovery company founded in 2024 by Joshua Meier (chief executive), Jack Dent (president), Matthew McPartlon (chief technology officer) and Jacques Boitreaud. Its team came from OpenAI, Meta FAIR, Stripe and Google X, and it describes its work as predicting and reprogramming interactions between biomolecules.

Chai-1, released on 9 September 2024, predicts structures of proteins, small molecules, DNA and RNA. The company published weights and inference code under Apache 2.0 and reported 77 percent success on PoseBusters against 76 percent for AlphaFold3, with competitive results even when run without multiple sequence alignments.

Chai-2, announced in 2025 for de novo antibody design, is a separate model that sources describe as not openly released. Funding has included a $30 million seed round, a $70 million Series A in August 2025 led by Menlo Ventures and a $130 million Series B reported in January 2026.

Mission and ambitions

Chai aims to let scientists design medicines computationally by predicting and engineering molecular interactions.

Known for

  1. 01

    Chai-1 open structure prediction

  2. 02

    Apache 2.0 weights and code

  3. 03

    Chai-2 antibody design

Milestones

  1. 2024

    Company founded

    Founded in San Francisco by Meier, Dent, McPartlon and Boitreaud.

  2. 2024

    Chai-1 released

    Open biomolecular structure model with Apache 2.0 weights and code, plus a free web interface.

  3. 2025

    Series A

    A $70 million round led by Menlo Ventures, reported by Business Wire.

  4. 2025

    Chai-2 antibody design

    A generative model for de novo antibody design, announced in 2025.

  5. 2026

    Series B

    A $130 million round led by General Catalyst and Oak HC/FT, reported by GEN.

Open source

Research papers

Notable releases

Openness

Open weights and code.

People

  • Joshua MeierCo-founder and chief executive

    Previously at Absci, Facebook AI and OpenAI.

Listed from the lab's own pages and public profiles.

Contact and community

Contact details and links are on the lab's website (https://www.chaidiscovery.com); code questions go through issues on their GitHub organisation.

Sources

Compiled from the lab's public pages, Hugging Face and GitHub. Last checked 2026-11-17. Something wrong or out of date? Tell us on Discord.

Labs nearby